검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PD-1 / PD-L1 monoclonal antibody (PD-1 / PD-L1 monoclonal antibody) Repertoire Immune Medicines·PD-1 ORR 59%·t½ 132 days |
|---|---|
Overview Program | PD-1 / PD-L1 monoclonal antibody |
Overview Company | Repertoire Immune Medicines |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Advanced Malignant Solid Tumor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted engagement of tumor-associated antigen |
MoA Biomarker | biomarkers, exploring different combination treatment models, and identifying the potential mechanisms of pri |
PK/PD Half-life | 132 days |
PK/PD Species | Mouse, objective response rates (ORRs), clinical benefit rate, and toxicity. |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, objective response rates (ORRs), clinical benefit rate, and toxicity. |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | pneumonitis) |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PD-1 / PD-L1 monoclonal antibody (PD-1 / PD-L1 monoclonal antibody) Repertoire Immune Medicines·PD-1 ORR 59%·t½ 132 days |
|---|---|
Overview Program | PD-1 / PD-L1 monoclonal antibody |
Overview Company | Repertoire Immune Medicines |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Advanced Malignant Solid Tumor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted engagement of tumor-associated antigen |
MoA Biomarker | biomarkers, exploring different combination treatment models, and identifying the potential mechanisms of pri |
PK/PD Half-life | 132 days |
PK/PD Species | Mouse, objective response rates (ORRs), clinical benefit rate, and toxicity. |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, objective response rates (ORRs), clinical benefit rate, and toxicity. |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | pneumonitis) |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교